NASDAQ:FBRX Forte Biosciences (FBRX) Stock Price, News & Analysis → We recommended Nvidia in 2016, now we’re recommending this… (From Porter & Company) (Ad) Free FBRX Stock Alerts $0.56 -0.01 (-1.77%) (As of 06/13/2024 ET) Add Compare Share Share Today's Range$0.56▼$0.5950-Day Range$0.55▼$0.7852-Week Range$0.38▼$1.06Volume2,399 shsAverage Volume27,737 shsMarket Capitalization$20.26 millionP/E RatioN/ADividend YieldN/APrice Target$3.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Forte Biosciences alerts: Email Address Forte Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside507.0% Upside$3.38 Price TargetShort InterestHealthy0.05% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.88Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.59) to ($0.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.40 out of 5 starsMedical Sector243rd out of 917 stocksPharmaceutical Preparations Industry106th out of 431 stocks 3.3 Analyst's Opinion Consensus RatingForte Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageForte Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about Forte Biosciences' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.05% of the outstanding shares of Forte Biosciences have been sold short.Short Interest Ratio / Days to CoverForte Biosciences has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Forte Biosciences has recently decreased by 32.27%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldForte Biosciences does not currently pay a dividend.Dividend GrowthForte Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FBRX. Previous Next 3.3 News and Social Media Coverage News SentimentForte Biosciences has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Forte Biosciences this week, compared to 0 articles on an average week.Search Interest1 people have searched for FBRX on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Forte Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Forte Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders10.53% of the stock of Forte Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.63% of the stock of Forte Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Forte Biosciences' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Forte Biosciences are expected to grow in the coming year, from ($0.59) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Forte Biosciences is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Forte Biosciences is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioForte Biosciences has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Forte Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyThe last Republican president?History shows Donald Trump is poised to go down as the last Republican President for a generation or more. How is this possible, with Biden so unpopular, and Trump running at least neck-in-neck with him in polls?This presentation explains exactly why. About Forte Biosciences Stock (NASDAQ:FBRX)Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Read More FBRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FBRX Stock News HeadlinesJune 13 at 3:40 AM | americanbankingnews.comForte Biosciences Target of Unusually High Options Trading (NASDAQ:FBRX)May 21, 2024 | finance.yahoo.comCompanies Like Forte Biosciences (NASDAQ:FBRX) Could Be Quite RiskyMay 17, 2024 | businesswire.comForte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing RulesMay 13, 2024 | investorplace.comFBRX Stock Earnings: Forte Biosciences Reported Results for Q1 2024May 13, 2024 | businesswire.comForte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business UpdateApril 10, 2024 | benzinga.comForte Biosciences Stock (NASDAQ:FBRX), Analyst Ratings, Price Targets, PredictionsApril 8, 2024 | markets.businessinsider.comBuy Recommendation for Forte Biosciences on Strong Potential of Novel FB-102 Treatment and Market PositionMarch 19, 2024 | investorplace.comFBRX Stock Earnings: Forte Biosciences Reported Results for Q4 2023March 18, 2024 | businesswire.comForte Biosciences, Inc. Announces 2023 Results and Provides Business UpdateDecember 12, 2023 | morningstar.comForte Biosciences Inc Ordinary SharesDecember 9, 2023 | finance.yahoo.comWe Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth CarefullyNovember 15, 2023 | morningstar.comForte Biosciences Inc Ordinary Shares FBRXNovember 14, 2023 | msn.comForte Biosciences GAAP EPS of -$0.26November 13, 2023 | finance.yahoo.comForte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business UpdateSeptember 14, 2023 | benzinga.comISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company's Upcoming Annual MeetingSeptember 14, 2023 | finance.yahoo.comISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company’s Upcoming Annual MeetingSeptember 6, 2023 | finance.yahoo.comConcerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company’s BoardroomAugust 25, 2023 | businesswire.comConcerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to StockholdersAugust 25, 2023 | 247wallst.comCamac Fund Now Owns 4.3% of Forte BiosciencesAugust 14, 2023 | finance.yahoo.comForte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business UpdateAugust 3, 2023 | benzinga.comChief Financial Officer At This Health Care Company Buys $149K of StockAugust 1, 2023 | finance.yahoo.comForte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102July 4, 2023 | finance.yahoo.comThis Forte Biosciences Insider Increased Their Holding In The Last YearMay 24, 2023 | finance.yahoo.comWe're Not Very Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn RateMay 19, 2023 | finance.yahoo.comForte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing RulesSee More Headlines Receive FBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Forte Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today6/14/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FBRX CUSIPN/A CIK1419041 Webwww.fortebiorx.com Phone(310) 618-6994FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Stock Price Target$3.38 High Stock Price Target$4.00 Low Stock Price Target$2.75 Potential Upside/Downside+507.0%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,480,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-99.44% Return on Assets-85.68% Debt Debt-to-Equity RatioN/A Current Ratio9.45 Quick Ratio9.45 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.97 per share Price / Book0.57Miscellaneous Outstanding Shares36,440,000Free Float32,605,000Market Cap$20.26 million OptionableOptionable Beta0.21 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Paul A. Wagner Ph.D. (Age 54)CEO, President & Chairman Comp: $960.23kMr. Antony A. Riley CPA (Age 57)Chief Financial Officer Comp: $568.48kDr. Barbara K. Finck M.D. (Age 77)Chief Medical Clinician & Director Comp: $45kMr. Christopher RoenfeldtChief Operating OfficerMr. Steven Ruhl (Age 67)Chief Technical Officer Key CompetitorsVerastemNASDAQ:VSTMPMV PharmaceuticalsNASDAQ:PMVPOramed PharmaceuticalsNASDAQ:ORMPSCYNEXISNASDAQ:SCYXSELLAS Life Sciences GroupNASDAQ:SLSView All CompetitorsInsidersPaul A WagnerBought 10,000 shares on 12/18/2023Total: $7,500.00 ($0.75/share)Paul A WagnerBought 10,520 shares on 12/13/2023Total: $7,364.00 ($0.70/share)Paul A WagnerBought 25,000 shares on 12/11/2023Total: $16,250.00 ($0.65/share)Paul A WagnerBought 36,203 shares on 12/7/2023Total: $20,997.74 ($0.58/share)Paul A WagnerBought 400 shares on 11/22/2023Total: $172.00 ($0.43/share)View All Insider Transactions FBRX Stock Analysis - Frequently Asked Questions Should I buy or sell Forte Biosciences stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Forte Biosciences in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" FBRX shares. View FBRX analyst ratings or view top-rated stocks. What is Forte Biosciences' stock price target for 2024? 3 analysts have issued 1 year price objectives for Forte Biosciences' stock. Their FBRX share price targets range from $2.75 to $4.00. On average, they anticipate the company's share price to reach $3.38 in the next year. This suggests a possible upside of 507.0% from the stock's current price. View analysts price targets for FBRX or view top-rated stocks among Wall Street analysts. How have FBRX shares performed in 2024? Forte Biosciences' stock was trading at $0.8217 on January 1st, 2024. Since then, FBRX shares have decreased by 32.3% and is now trading at $0.5560. View the best growth stocks for 2024 here. Are investors shorting Forte Biosciences? Forte Biosciences saw a decrease in short interest in the month of May. As of May 31st, there was short interest totaling 17,000 shares, a decrease of 32.3% from the May 15th total of 25,100 shares. Based on an average trading volume of 23,800 shares, the short-interest ratio is presently 0.7 days. View Forte Biosciences' Short Interest. When is Forte Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our FBRX earnings forecast. How were Forte Biosciences' earnings last quarter? Forte Biosciences, Inc. (NASDAQ:FBRX) announced its quarterly earnings data on Monday, May, 13th. The company reported ($0.16) earnings per share (EPS) for the quarter. What other stocks do shareholders of Forte Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Forte Biosciences investors own include Trevena (TRVN), Chimerix (CMRX), electroCore (ECOR), Great Panther Mining (GPL), Immunic (IMUX), Infinera (INFN) and Stride (LRN). How do I buy shares of Forte Biosciences? Shares of FBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FBRX) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially ...Market JAR | SponsoredBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of ne...Chaikin Analytics | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredLike Investing in Big Tech in the Early 2000s?More than a decade after the first Bitcoin was mined, people are finally realizing something very important......Manward Press | SponsoredAn utter travestyThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Forte Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Forte Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.